SCHEMBL4170549

SCHEMBL4170549

Cc1ccc2c(c1)C1(NC(=O)NC1=O)C(=O)N2CCOc1ccccc1

nearest known ligand 0.52

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 11/20 0.52
LMNA P02545 8/20 0.52
MAPT P10636 7/20 0.52
KMT2A Q03164 7/20 0.46
L3MBTL1 Q9Y468 2/20 0.46
GAA P10253 1/20 0.46
PLA2G7 Q13093 2/20 0.44
MEN1 O00255 5/20 0.43
RCE1 Q9Y256 2/20 0.43
TDP1 Q9NUW8 3/20 0.43
POLB P06746 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
MAPK1 P28482 4/20 0.43
TSHR P16473 3/20 0.43
HPGD P15428 2/20 0.43
HTT P42858 2/20 0.43
NPSR1 Q6W5P4 1/20 0.43
RAB9A P51151 3/20 0.42
NPC1 O15118 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4159430 0.90 PLA2G7 (0.50) ALDH1A1LMNAMAPTKMT2APLA2G7
SCHEMBL4166000 0.87 HPGD (0.46) ALDH1A1LMNAMAPTGAAPLA2G7
SCHEMBL4176442 0.87 AKR1A1 (0.46) ALDH1A1LMNAMAPTGAAPLA2G7
SCHEMBL4169530 0.87 L3MBTL1 (0.42) ALDH1A1LMNAMAPTL3MBTL1GAA
SCHEMBL4164829 0.85 AKR1B1 (0.41) ALDH1A1LMNAMAPTKMT2AL3MBTL1
SCHEMBL4171124 0.84 AKR1B1 (0.39) ALDH1A1LMNAMAPTKMT2AL3MBTL1
SCHEMBL4169551 0.84 ALDH1A1 (0.51) ALDH1A1LMNAMAPTKMT2AL3MBTL1
SCHEMBL4170928 0.81 AKR1B1 (0.39) ALDH1A1LMNAMAPTKMT2AL3MBTL1
SCHEMBL4259885 0.81 ADAMTS5 (0.52) ALDH1A1LMNAMAPTKMT2AMEN1
SCHEMBL4167219 0.81 PLA2G7 (0.51) PLA2G7RAB9ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090076049-A1 Novel Spiro [Imidazolidine-4, 3' -Indole] 2, 2', 5' (1H) Triones for Treatment of Conditions Associated with Vanilloid Receptor 1 ASTRAZENECA AB (SE) 2009-03-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090076049-A1 Novel Spiro [Imidazolidine-4, 3' -Indole] 2, 2', 5' (1H) Triones for Treatment of Conditions Associated with Vanilloid Receptor 1 TRPV1, TRPV5, TRPV2 ALDH1A1 550/4885LMNA 3199/4885MAPT 2775/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.